Med BioGene Inc. | Balance Sheet

Fiscal year is January-December. All values CAD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
192.90
167.10
31.90
61.00
0.80
3.30
Total Accounts Receivable
2.50
7.50
4.90
1.30
0.90
0.50
Total Current Assets
195.30
174.70
36.80
62.30
1.70
4.70
Total Assets
195.30
174.70
36.80
62.30
1.70
4.70
Accounts Payable
65.30
72.30
-
-
-
Other Current Liabilities
10.40
146.80
120.50
68.70
113.60
Total Current Liabilities
75.70
219.00
120.50
68.70
113.60
Total Liabilities
75.70
219.00
120.50
68.70
113.60
Common Equity (Total)
119.70
44.40
83.70
6.40
111.80
Total Shareholders' Equity
119.70
44.40
83.70
6.40
111.80
Total Equity
119.70
44.40
83.70
6.40
111.80
Liabilities & Shareholders' Equity
195.30
174.70
36.80
62.30
1.70

About Med BioGene

View Profile
Address
598 East Kent Avenue South
Vancouver British Columbia V5X 4V6
Canada
Employees -
Website http://www.medbiogene.com
Updated 07/08/2019
Med BioGene, Inc. operates as a life science company, which engages in the development and commercialization of genomic-based clinical laboratory diagnostic tests. It focuses on managing the license and rights for GeneFx Lung, prognostic genomic-based test for non-small-cell lung cancer. The company was founded on April 28, 2006 and is headquartered in Vancouver, Canada.